No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study

Background: No evidence of disease activity (NEDA) is a composite endpoint being increasingly applied as an outcome measure in clinical trials as well as proposed for individual therapeutic decisions in multiple sclerosis (MS). Objective: Assess the proportion of patients with relapsing-remitting MS...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Multiple sclerosis 2017-11, Vol.23 (13), p.1736-1747
Hauptverfasser:	Kappos, Ludwig, Havrdova, Eva, Giovannoni, Gavin, Khatri, Bhupendra O, Gauthier, Susan A, Greenberg, Steven J, You, Xiaojun, Wang, Ping, Giannattasio, Giorgio
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvants, Immunologic - administration & dosage Adjuvants, Immunologic - pharmacology Adult Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - pharmacology Clinical trials Female Gadolinium Humans Immunoglobulin G - administration & dosage Immunoglobulin G - pharmacology Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - pharmacology Immunotherapy Injections, Intramuscular Injections, Subcutaneous Interferon Interferon beta-1a - administration & dosage Interferon beta-1a - pharmacology Magnetic resonance imaging Male Middle Aged Monoclonal antibodies Multiple sclerosis Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging Multiple Sclerosis, Relapsing-Remitting - drug therapy Multiple Sclerosis, Relapsing-Remitting - physiopathology NMR Nuclear magnetic resonance Outcome Assessment (Health Care) - methods Regression analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!